跳至主要内容
临床试验/JPRN-jRCT1061210010
JPRN-jRCT1061210010招募中2 期

Efficacy and safety of zoledronic acid for postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor. - SBP-15

Tadahiko Shien0 个研究点目标入组 200 人开始时间: 2021年6月7日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • ER positive postmenopausal breast cancer patients
  • Patients recieving AI (<2 yerars)
  • Patients diagnosed osteoporosis
  • Patients without treatment of osteoporosis
  • CCr>35mL/min
  • Serum Ca>8.0 mg/dL
  • Without dental treatment
  • With informed consent

排除标准

  • Metastatic breast cancer patients
  • Allargy with bisphosphonate
  • Renal disfunction
  • Active other cancers
  • Treated with bisphosphonate
  • The medical doctor judged ineligible

研究者

发起方
Tadahiko Shien

相似试验